Related Experiment Video
Updated: Feb 16, 2026
07:00
qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping
Published on: May 25, 2015
17.9K
Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework
Lan Xu1, Anja Oštrbenk2, Mario Poljak2
1Belgian Cancer Centre/Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium.
Summary
The Roche Linear Array HPV genotyping test demonstrates high clinical accuracy for cervical cancer screening, showing sensitivity and specificity comparable to existing methods. This validated test meets requirements for primary screening using high-risk HPV detection.
Area of Science:
- Gynecology
- Oncology
- Virology
Background:
- Cervical cancer screening is transitioning from cytology to high-risk (hr) HPV testing.
- Clinical validation of HPV tests is crucial for effective implementation in practice.
Purpose of the Study:
- To evaluate the clinical performance of the Roche Linear Array HPV genotyping test.
- To assess the Linear Array's utility within the VALGENT-3 framework for cervical cancer screening.
Main Methods:
- The VALGENT-3 framework involved 1600 Slovenian women's samples.
- Linear Array detected 37 HPV types, with hrHPV defined by 13 types common to Hybrid Capture 2 (HC2).
- Sensitivity for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and specificity for
Main Results:
- Linear Array achieved 97.6% sensitivity and 91.7% specificity for CIN2+.
- Relative to HC2, Linear Array showed non-inferior performance (sensitivity 1.02, specificity 1.02).
- Prevalence of hrHPV was 10.5%, with HPV16 and HPV18 at 2.3% and 0.9% respectively; excellent agreement was found with the RealTime test.
Conclusions:
- The Linear Array test demonstrated high clinical accuracy for detecting CIN2+.
- It offers comparable sensitivity and improved specificity versus HC2 for cervical cancer screening.
- The test's ability to detect 13 hrHPV types meets clinical accuracy standards for primary screening.
